The DOI matches its Crossref record; 51 of the 52 references it cites were found in a registry or an index.
Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2
Open accessPreprint — published as 10.1126/sciimmunol.abl4509 · Paper page
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused more than 160 million infections and more than 3 million deaths worldwide. While effective vaccines are currently being deployed, the adaptive immune determinants which promote viral clearance and confer protection remain poorly defined. Using mouse models of SARS-CoV-2, we demonstrate that both humoral and cellular adaptive immunity contributes to viral clearance in the setting of primary infection. Furthermore, we find that either convalescent mice, or mice that receive mRNA vaccination are protected from both homologous infection and infection with a variant of concern, B.1.351. Additionally, we find this protection to be largely mediated by antibody response and not cellular immunity. These results highlight the in vivo protective capacity of antibodies generated to both vaccine and natural infection. One-Sentence Summary: Defining the roles of humoral and cellular adaptive immunity in viral clearance and protection from SARS-CoV-2 and a variant of concern.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Neutralizing antibodies are a likely correlate of protection against SARS-CoV-2 infection, as suggested by vaccine efficacy studies, preclinical studies in mice and non-human primates, and data from the early use of convalescent plasma in elderly patients 4,5,10,13,14,18,23 .”
From Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2 (2021) · cites this paper as [5]
In the citing paper
“Although it is increasingly recognized that neutralizing antibodies dominate protection against initial infection 4,13 , T cells might limit disease progression 5 when neutralizing antibody titres are low 14 .”
From Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2 (2021) · cites this paper as [5]
In the citing paper
“There is increasing evidence that neutralizing responses are a correlate of protection [4][5][6] .”
From Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2 (2021) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021) · Nature Medicine · doi:10.1038/s41591-021-01377-8 · Cited by 3,742
Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.015 · Cited by 3,595
RAG-1-deficient mice have no mature B and T lymphocytes
Mombaerts, P., Iacomini, J., Johnson, R. S., Herrup, K., Tonegawa, S., & Papaioannou, V. E. (1992) · Cell · doi:10.1016/0092-8674(92)90030-g · Cited by 2,898
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.
Dan, J. M., Mateus, J., Kato, Y., Hastie, K. M., Yu, E. D., Faliti, C. E., Grifoni, A., Ramirez, S. I., Haupt, S., Frazier, A., et al. (2021) · Science · doi:10.1126/science.abf4063 · Cited by 2,656
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101765 · Cited by 2,527
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
Planas, D., Veyer, D., Baidaliuk, A., Staropoli, I., Guivel-Benhassine, F., Rajah, M. M., Planchais, C., Porrot, F., Robillard, N., Puech, J., et al. (2021) · Nature · doi:10.1038/s41586-021-03777-9 · Cited by 1,992
Rydyznski Moderbacher, C., Ramirez, S. I., Dan, J. M., Grifoni, A., Hastie, K. M., Weiskopf, D., Belanger, S., Abbott, R. K., Kim, C., Choi, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.038 · Cited by 1,790
Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19
Sekine, T., Perez-Potti, A., Rivera-Ballesteros, O., Strålin, K., Gorin, J.-B., Olsson, A., Llewellyn-Lacey, S., Kamal, H., Bogdanovic, G., Muschiol, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.017 · Cited by 1,788
Cited by
Sorted by citations
Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2
Collier, D. A., Ferreira, I. A. T. M., Kotagiri, P., Datir, R. P., Lim, E. Y., Touizer, E., Meng, B., Abdullahi, A., The CITIID-NIHR BioResource COVID-19 Collaboration, Principal Investigators, et al. (2021) · Nature · doi:10.1038/s41586-021-03739-1 · Cited by 751
Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine
Li, C., Lee, A., Grigoryan, L., Arunachalam, P. S., Scott, M. K. D., Trisal, M., Wimmers, F., Sanyal, M., Weidenbacher, P. A., Feng, Y., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01163-9 · Cited by 505
PI3K inhibitors are finally coming of age
Vanhaesebroeck, B., Perry, M. W. D., Brown, J. R., André, F., & Okkenhaug, K. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00209-1 · Cited by 494
Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant
Gao, Y., Cai, C., Grifoni, A., Müller, T. R., Niessl, J., Olofsson, A., Humbert, M., Hansson, L., Österborg, A., Bergman, P., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01700-x · Cited by 409
Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination
Tang, J., Zeng, C., Cox, T. M., Li, C., Son, Y. M., Cheon, I. S., Wu, Y., Behl, S., Taylor, J. J., Chakaraborty, R., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.add4853 · Cited by 364
Immune boosting by B.1.1.529 ( Omicron) depends on previous SARS-CoV-2 exposure
Reynolds, C. J., Pade, C., Gibbons, J. M., Otter, A. D., Lin, K., Sandoval, D. M., Pieper, F. P., Butler, D. K., Liu, S., Joy, G., et al. (2022) · Science · doi:10.1126/science.abq1841 · Cited by 325
Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses
Mao, T., Israelow, B., Peña-Hernández, M. A., Suberi, A., Zhou, L., Luyten, S., Reschke, M., Dong, H., Homer, R., Saltzman, W. M., et al. (2022) · Science · doi:10.1126/science.abo2523 · Cited by 356
Self-citationCOVID-19 vaccination: The road ahead
Altmann, D. M., & Boyton, R. J. (2022) · Science · doi:10.1126/science.abn1755 · Cited by 198
Wong, L.-Y. R., & Perlman, S. M. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00656-2 · Cited by 202
Fendler, A., Shepherd, S. T. C., Au, L., Wilkinson, K. A., Wu, M., Byrne, F., Cerrone, M., Schmitt, A. M., Joharatnam‐Hogan, N., Shum, B., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00274-w · Cited by 172
Polymer nanoparticles deliver mRNA to the lung for mucosal vaccination
Suberi, A., Grun, M. K., Mao, T., Israelow, B., Reschke, M., Grundler, J., Akhtar, L., Lee, T., Shin, K., Piotrowski-Daspit, A. S., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abq0603 · Cited by 190
Self-citationSARS-CoV-2 in immunocompromised individuals
DeWolf, S., Laracy, J. C., Perales, M., Kamboj, M., van den Brink, M. R. M., & Vardhana, S. A. (2022) · Immunity · doi:10.1016/j.immuni.2022.09.006 · Cited by 143
SARS-CoV-2 infections in children: Understanding diverse outcomes
Brodin, P. (2022) · Immunity · doi:10.1016/j.immuni.2022.01.014 · Cited by 118
van Gils, M. J., Lavell, A. H. A., van der Straten, K., Appelman, B., Bontjer, I., Poniman, M., Burger, J. A., Oomen, M., Bouhuijs, J. H., van Vught, L. A., et al. (2022) · PLoS Medicine · doi:10.1371/journal.pmed.1003991 · Cited by 104
Sabatino, J. J., Mittl, K., Rowles, W. M., McPolin, K., Rajan, J. V., Laurie, M. T., Zamecnik, C. R., Dandekar, R., Alvarenga, B. D., Loudermilk, R. P., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.156978 · Cited by 105
Animal models for COVID-19: advances, gaps and perspectives
Fan, C., Wu, Y., Xiong, R., Yang, Y., Ling, C., Liu, S., Liu, S., & Wang, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01087-8 · Cited by 110
SARS‐CoV‐2 infection and multi-organ system damage: A review
Rabaan, A. A., Smajlović, S., Tombuloğlu, H., Ćordić, S., Hajdarević, A., Kudić, N., Mutai, A. A., Turkistani, S. A., Al-Ahmed, S. H., Al-Zaki, N. A., et al. (2022) · Biomolecules and Biomedicine · doi:10.17305/bjbms.2022.7762 · Cited by 107
Persistent SARS-CoV-2 infection and intra-host evolution in association with advanced HIV infectionPreprint
Karim, F., Moosa, M.-Y. S., Gosnell, B., Cele, S., Giandhari, J., Pillay, S., Tegally, H., Wilkinson, E., San, J., Msomi, N., et al. (2021) · medRxiv · doi:10.1101/2021.06.03.21258228 · Cited by 105
Lee, A. W. Q., Floyd, K. A., Wu, S., Fang, Z., Tan, T.-K., Froggatt, H. M., Powers, J. M., Leist, S. R., Gully, K. L., Hubbard, M. L., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01700-0 · Cited by 106
Townsend, J. P., Hassler, H. B., Sah, P., Galvani, A. P., & Dornburg, A. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2204336119 · Cited by 85
Charmetant, X., Espi, M., Benotmane, I., Barateau, V., Heibel, F., Buron, F., Gautier-Vargas, G., Delafosse, M., Perrin, P., Koenig, A., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abl6141 · Cited by 84
Niessl, J., Sekine, T., & Buggert, M. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101505 · Cited by 77
Gao, Y., Cai, C., Wullimann, D., Niessl, J., Rivera‐Ballesteros, O., Chen, P., Lange, J., Cuapio, A., Blennow, O., Hansson, L., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.07.005 · Cited by 73
The immune response to SARS-CoV-2 in people with HIV
Höft, M. A., Burgers, W. A., & Riou, C. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01087-w · Cited by 81
A stem-loop RNA RIG-I agonist protects against acute and chronic SARS-CoV-2 infection in mice
Mao, T., Israelow, B., Lucas, C. G. D. O., Vogels, C. B. F., Gomez-Calvo, M. L., Fedorova, O., Breban, M. I., Menasché, B. L., Dong, H., Linehan, M. M., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20211818 · Cited by 70
Self-citationRole of Senescence and Aging in SARS-CoV-2 Infection and COVID-19 Disease
Lynch, S. M., Guo, G., Gibson, D. S., Bjourson, A. J., & Singh, T. (2021) · Cells · doi:10.3390/cells10123367 · Cited by 70
The mysterious origins of the Omicron variant of SARS-CoV-2
Du, P., Gao, G. F., & Wang, Q. (2022) · The Innovation · doi:10.1016/j.xinn.2022.100206 · Cited by 69
Instructing durable humoral immunity for COVID-19 and other vaccinable diseases
Bhattacharya, D. (2022) · Immunity · doi:10.1016/j.immuni.2022.05.004 · Cited by 64
Mao, T., Israelow, B., Suberi, A., Zhou, L., Reschke, M., Peña-Hernández, M. A., Dong, H., Homer, R. J., Saltzman, W., & Iwasaki, A. (2022) · bioRxiv · doi:10.1101/2022.01.24.477597 · Cited by 57
Self-citationModeling how antibody responses may determine the efficacy of COVID-19 vaccines
Padmanabhan, P., Desikan, R., & Dixit, N. M. (2022) · Nature Computational Science · doi:10.1038/s43588-022-00198-0 · Cited by 57
Fumagalli, V., Ravà, M., Marotta, D., Lucia, P. D., Bono, E. B., Giustini, L., Leo, F. D., Casalgrandi, M., Monteleone, E., Mouro, V., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-01787-z · Cited by 61
Guardians of the oral and nasopharyngeal galaxy: IgA and protection against SARS‐CoV ‐2 infection*
Sheikh‐Mohamed, S., Sanders, E. C., Gommerman, J. L., & Tal, M. C. (2022) · Immunological Reviews · doi:10.1111/imr.13118 · Cited by 57
Horiuchi, S., Oishi, K., Carrau, L., Frere, J. J., Møller, R., Panis, M., & tenOever, B. R. (2021) · Science Immunology · doi:10.1126/sciimmunol.abm3131 · Cited by 45
Pasquini, Z. A. I., Toschi, A., Casadei, B., Pellegrini, C., D’Abramo, A., Vita, S., Beccacece, A., Bussini, L., Chionsini, M. C., Dentale, N., et al. (2023) · Hematological Oncology · doi:10.1002/hon.3206 · Cited by 48
T‐cell recovery and evidence of persistent immune activation 12 months after severe COVID ‐19
Taeschler, P., Adamo, S., Deng, Y., Cervia, C., Zurbuchen, Y., Chevrier, S., Raeber, M. E., Hasler, S., Bächli, E., Rudiger, A., et al. (2022) · Allergy · doi:10.1111/all.15372 · Cited by 51
Ying, B., Darling, T. L., Desai, P., Liang, C.-Y., Dmitriev, I. P., Soudani, N., Bricker, T. L., Kashentseva, E. A., Harastani, H., Raju, S., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-01743-x · Cited by 49
Immunologic Interplay Between HIV/AIDS and COVID-19: Adding Fuel to the Flames?
Augello, M., Bono, V., Rovito, R., Tincati, C., & Marchetti, G. C. (2023) · Current HIV/AIDS Reports · doi:10.1007/s11904-023-00647-z · Cited by 48
Vaccine-induced protection against SARS-CoV-2 requires IFN-γ-driven cellular immune response
Wang, X., Yuen, T. T., Dou, Y., Hu, J., Li, R., Zeng, Z., Lin, X., Gong, H., Chan, C. H.-C., Yoon, C., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39096-y · Cited by 42
Enhanced inhibition of MHC-I expression by SARS-CoV-2 Omicron subvariants
Moriyama, M., Lucas, C. G. D. O., Monteiro, V. S., Initiative, Y. S.-C.-2. G. S., Iwasaki, A., Chen, N., Breban, M. I., Hahn, A. M., Pham, K., Koch, T. R., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2221652120 · Cited by 56
Self-citationNew insights into the pathogenesis of SARS-CoV-2 during and after the COVID-19 pandemic
Carvajal, J. J., García-Castillo, V., Cuellar, S. V., Campillay-Véliz, C. P., Salazar‐Ardiles, C., Avellaneda, A. M., Muñoz, C. A., Retamal-Díaz, A. R., Bueno, S. M., González, P. A., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1363572 · Cited by 42
Nelson, C. E., Namasivayam, S., Foreman, T. W., Kauffman, K. D., Sakai, S., Dorosky, D. E., Lora, N. E., Program, N. T. I., Brooks, K., Potter, E. L., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abo0535 · Cited by 36
COVID-19 and the Immune Response: A Multi-Phasic Approach to the Treatment of COVID-19
Sapir, T., Averch, Z., Lerman, B., Bodzin, A., Fishman, Y., & Maitra, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158606 · Cited by 34
Lung Tissue-Resident Memory T cells: The Gatekeeper To Respiratory Viral (Re)-Infection
Tang, J., & Sun, J. (2022) · Current Opinion in Immunology · doi:10.1016/j.coi.2022.102278 · Cited by 39
IL-9 aggravates SARS-CoV-2 infection and exacerbates associated airway inflammation
Sadhu, S., Dalal, R., Dandotiya, J., Binayke, A., Singh, V., Tripathy, M. R., Das, V., Goswami, S., Kumar, S., Rizvi, Z. A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39815-5 · Cited by 36
The kinetics of SARS-CoV-2 infection based on a human challenge study
Iyaniwura, S. A., Ribeiro, R. M., Zitzmann, C., Phan, T., Ke, R., & Perelson, A. S. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2406303121 · Cited by 40
Olfactory immune response to SARS-CoV-2
Wellford, S. A., & Moseman, E. A. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01119-5 · Cited by 36
Post-vaccination T cell immunity to omicron
Jacobsen, H., Jiménez, V. C., Sitaras, I., Bar‐Zeev, N., Čičin‐Šain, L., Higdon, M. M., & Knoll, M. D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.944713 · Cited by 30
Human coronavirus OC43-elicited CD4+ T cells protect against SARS-CoV-2 in HLA transgenic mice
Alves, R. P. D. S., Timis, J., Miller, R., Valentine, K. M., Pinto, P. B. A., Gonzalez, A., Regla-Nava, J. Á., Maule, E., Nguyen, M. N., Shafee, N., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45043-2 · Cited by 29
Lukeman, H., Al-Wassiti, H. A., Fabb, S. A., Lim, L., Wang, T., Britton, W. J., Steain, M. C., Pouton, C. W., Triccas, J. A., & Counoupas, C. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105599 · Cited by 38
Stevens, K., Frangou, E. A., Shin, J. I., Anders, H., Bruchfeld, A. N., Schönermarck, U., Hauser, T., Westman, K. W. A., Juarez, G. M. F., Floege, J., et al. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac052 · Cited by 28
Spencer, A. J., Morris, S. J., Ulaszewska, M., Powers, C., Kailath, R., Bissett, C., Truby, A., Thakur, N., Newman, J., Allen, E. R., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103902 · Cited by 31
Montgomerie, I., Bird, T. W., Palmer, O. R., Mason, N. C., Pankhurst, T. E., Lawley, B., Hernández, L. C., Harfoot, R., Authier-Hall, A., Anderson, D. E., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106256 · Cited by 27
Oyesola, O. O., Hilligan, K. L., Namasivayam, S., Howard, N., Clancy, C. S., Zhao, M., Oland, S. D., Kiwanuka, K. N., Garza, N. L., Lafont, B. A. P., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.adf8161 · Cited by 33
T Cells Targeting SARS-CoV-2: By Infection, Vaccination, and Against Future Variants
Nguyen, T. H. O., Cohen, C. A., Rowntree, L. C., Bull, M. B., Hachim, A., Kedzierska, K., & Valkenburg, S. A. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.793102 · Cited by 24
Lenart, K., Cerveira, R. A., Hellgren, F., Ols, S., Sheward, D. J., Kim, C., Cagigi, A., Gagné, M., Davis, B. J., Germosen, D., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00806-2 · Cited by 26
Repertoires of SARS-CoV-2 epitopes targeted by antibodies vary according to severity of COVID-19
Gregory, D. J., Vannier, A., Duey, A. H., Roady, T. J., Dzeng, R. K., Pavlovic, M., Chapin, M. H., Mukherjee, S., Wilmot, H., Chronos, N., et al. (2022) · Virulence · doi:10.1080/21505594.2022.2073025 · Cited by 23
Vega, M. D., Olivera, D., Davanzo, G. G., Bertullo, M., Noya, V., de Souza, G. F., Muraro, S. P., de Castro, Í. M. S., Arévalo, A. P., Crispo, M., et al. (2022) · Science Advances · doi:10.1126/sciadv.abn6545 · Cited by 26
Sokhansanj, B. A., Zhao, Z., & ROSEN, G. L. (2022) · Biology · doi:10.3390/biology11121786 · Cited by 27
How to Provide the Needed Protection from COVID-19 to Patients with Hematologic Malignancies
Ribas, A., Dhodapkar, M. V., Campbell, K. M., Davies, F. E., Gore, S. D., Levy, R., & Greenberger, L. M. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0166 · Cited by 24
Autophagy: The Potential Link between SARS-CoV-2 and Cancer
Habibzadeh, P., Dastsooz, H., Eshraghi, M., Łoś, M., Klionsky, D. J., & Ghavami, S. (2021) · Cancers · doi:10.3390/cancers13225721 · Cited by 24
mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant
Nanishi, E., McGrath, M. E., O’Meara, T. R., Barman, S., Yu, J., Wan, H., Dillen, C. A., Menon, M., Seo, H., Song, K., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03765-3 · Cited by 21
Corleis, B., Hoffmann, D., Rauch, S., Fricke, C., Roth, N., Gergen, J., Kovacikova, K., Schlottau, K., Halwe, N. J., Ulrich, L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36110-1 · Cited by 22
Paschold, L., Klee, B., Gottschick, C., Willscher, E., Diexer, S., Schultheiß, C., Simnica, D., Sedding, D., Girndt, M., Gekle, M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.876306 · Cited by 21
Considerations of CD8+ T Cells for Optimized Vaccine Strategies Against Respiratory Viruses
Hirai, T., & Yoshioka, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.918611 · Cited by 21
Li, X., Wang, L., Liu, J., Fang, E., Liu, X., Peng, Q., Zhang, Z., Li, M., Liu, X., Wu, X., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2097479 · Cited by 22
Phan, T., Zitzmann, C., Chew, K. W., Smith, D. M., Daar, E. S., Wohl, D. A., Eron, J. J., Currier, J. S., Hughes, M. D., Choudhary, M. C., et al. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1011680 · Cited by 24
Impact of Chronic HIV Infection on SARS-CoV-2 Infection, COVID-19 Disease and Vaccines
Yang, Y., & Iwasaki, A. (2021) · Current HIV/AIDS Reports · doi:10.1007/s11904-021-00590-x · Cited by 42
Self-citationTissue immunity to SARS‐CoV‐2: Role in protection and immunopathology*
Rybkina, K., Davis‐Porada, J., & Färber, D. L. (2022) · Immunological Reviews · doi:10.1111/imr.13112 · Cited by 19
Jangra, S., Landers, J. J., Laghlali, G., Rathnasinghe, R., Warang, P., Park, S., O’Konek, J. J., Singh, G., Janczak, K. W., García‐Sastre, A., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00691-1 · Cited by 20
Age-dependent acquisition of pathogenicity by SARS-CoV-2 Omicron BA.5
Imbiakha, B., Ezzatpour, S., Buchholz, D. W., Sahler, J., Ye, C., Olarte‐Castillo, X. A., Zou, A., Kwas, C. T., O’Hare, K., Choi, A., et al. (2023) · Science Advances · doi:10.1126/sciadv.adj1736 · Cited by 21
Measurement of IFN-γ and IL-2 for the assessment of the cellular immunity against SARS-CoV-2
Safont, G., Villar-Hernández, R., Smalchuk, D., Stojanović, Z., Marín, A., Lacoma, A., Pérez-Cano, C., López-Martínez, A., Molina-Moya, B., Solis, A. J., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-51505-w · Cited by 21
Baker, D., MacDougall, A. M., Kang, A. S., Schmierer, K., Giovannoni, G., & Dobson, R. (2021) · Clinical & Experimental Immunology · doi:10.1093/cei/uxab015 · Cited by 21
Animal models for COVID-19 and tuberculosis
Corleis, B., Bastian, M., Hoffmann, D., Beer, M., & Dorhoi, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1223260 · Cited by 21
O’Meara, T. R., Nanishi, E., McGrath, M. E., Barman, S., Dong, D., Dillen, C. A., Menon, M., Seo, H., Dhe‐Paganon, S., Ernst, R. K., et al. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2023.06.031 · Cited by 20
Harnessing mucosal immunity for protective vaccines
Kwon, D.-I., Bhagchandani, S. H., Ehrenzeller, S. A., & Iwasaki, A. (2026) · Nature reviews. Immunology · doi:10.1038/s41577-026-01273-7 · Cited by 25
Self-citationPlatelet and immune signature associated with a rapid response to the BNT162b2 mRNA COVID‐19 vaccine
Flego, D., Cesaroni, S., Romiti, G. F., Corica, B., Marrapodi, R., Scafa, N., Maiorca, F., Lombardi, L., Pallucci, D., Pulcinelli, F. M., et al. (2022) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15648 · Cited by 18
Ye, C., Park, J., Chiem, K., Dravid, P., Allué‐Guardia, A., Garcia‐Vilanova, A., Tamayo, P. P., Shivanna, V., Kapoor, A., Walter, M. R., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.00653-23 · Cited by 18
Slamanig, S., González‐Domínguez, I., Chang, L. A., Lemus, N., Lai, T. Y., Martínez, J. L., Singh, G., Dolange, V., Abdeljawad, A., Kowdle, S., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105185 · Cited by 20
Nahass, G. R., Salomon, R. E. A., Blacker, G., Haider, K., Brotherton, R., Teague, K., Yiu, Y. Y., Brewer, R. E., Galloway, S., Hansen, P. S., et al. (2021) · medRxiv · doi:10.1101/2021.08.22.21262168 · Cited by 20
Inhalable polymer nanoparticles for versatile mRNA delivery and mucosal vaccinationPreprint
Suberi, A., Grun, M. K., Mao, T., Israelow, B., Reschke, M., Grundler, J., Akhtar, L., Lee, T., Shin, K., Piotrowski-Daspit, A. S., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.22.485401 · Cited by 18
Self-citationObesity-compromised immunity in post-COVID-19 condition: a critical control point of chronicity
Jang, S.-W., Hong, W., & Moon, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1433531 · Cited by 17
Timofeeva, A. M., Sedykh, S. E., & Nevinsky, G. A. (2022) · Vaccines · doi:10.3390/vaccines10030384 · Cited by 17
Augello, M., Bono, V., Rovito, R., Tincati, C., Bianchi, S., Taramasso, L., Biagio, A. D., Callegaro, A., Maggiolo, F., Borghi, E., et al. (2023) · iScience · doi:10.1016/j.isci.2023.108673 · Cited by 16
Chen, Y., Song, W., Li, C., Wang, J., Liu, F., Ye, Z., Ren, P., Tong, Y., Li, J., Ou, Z., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104485 · Cited by 16
Ancestral SARS-CoV-2-specific T cells cross-recognize Omicron
Gao, Y., Cai, C., Grifoni, A., Müller, T. R., Niessl, J., Olofsson, A., Humbert, M., Hansson, L., Österborg, A., Bergman, P., et al. (2022) · Nature Medicine · doi:10.1038/d41591-022-00017-z · Cited by 20
Adaptive immune cells are necessary for SARS-CoV-2–induced pathology
Imbiakha, B., Sahler, J., Buchholz, D. W., Ezzatpour, S., Jager, M. C., Choi, A., Monreal, I. A., Byun, H., Adeleke, R. A., Leach, J. R., et al. (2024) · Science Advances · doi:10.1126/sciadv.adg5461 · Cited by 14
Low-Dose SARS-CoV-2 S-Trimer with an Emulsion Adjuvant Induced Th1-Biased Protective Immunity
Liao, H., Wu, W.-L., Chiang, C.-Y., Huang, M., Shen, K., Huang, Y., Wu, S., Liao, C., Chen, H., & Liu, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094902 · Cited by 15
SARS-CoV-2 Omicron subvariants evolved to promote further escape from MHC-I recognitionPreprint
Moriyama, M., Lucas, C., Monteiro, V., & Iwasaki, A. (2022) · bioRxiv · doi:10.1101/2022.05.04.490614 · Cited by 9
Self-citationYing, B., Darling, T. L., Desai, P., Liang, C.-Y., Dmitriev, I. P., Soudani, N., Bricker, T. L., Kashentseva, E. A., Harastani, H., Schmidt, A. G., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.04.539332 · Cited by 13
Moriyama, M., Rodrigues, G. R., Wang, J., Jayewickreme, R., Hudak, A., Dong, H., Homer, R., Ma, S., & Iwasaki, A. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2422171122 · Cited by 21
Self-citationUkey, R., Bruiners, N., Mishra, H. K., Mishra, P. K., McCloskey, D., Onyuka, A., Chen, F., Pinter, A., Weiskopf, D., Sette, A., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02252-0 · Cited by 16
Qiao, N., Hori, M., Naito, M., Chang, H., Ogura, S., Suzuki, M., Kimura, T., Fukushima, S., Kim, H. J., Uchida, S., et al. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123515 · Cited by 14
Lung T cell response in COVID-19
Shakiba, M. H., Gemünd, I. D., Beyer, M., & Bonaguro, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1108716 · Cited by 13
Uraki, R., Imai, M., Ito, M., Yamayoshi, S., Kiso, M., Jounai, N., Miyaji, K., Iwatsuki‐Horimoto, K., Takeshita, F., & Kawaoka, Y. (2024) · npj Vaccines · doi:10.1038/s41541-023-00800-0 · Cited by 14
Development and function of tissue-resident memory B cells
Chen, C., & Laidlaw, B. J. (2022) · Advances in immunology · doi:10.1016/bs.ai.2022.08.001 · Cited by 14
Chia, W. N., Tan, C. W., Tan, A. W. K., Young, B. E., Starr, T. N., López, E., Fibriansah, G., Barr, J. A., Cheng, S. M. S., Yeoh, A. Y.-Y., et al. (2023) · Science Advances · doi:10.1126/sciadv.ade3470 · Cited by 13
Ali, Y. M., Carnell, G., Fumagalli, S., Mercurio, D., Seminara, S., Lynch, N. J., Khatri, P., Arachchilage, C. H., Mascheroni, L., Kaminski, C. F., et al. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad462 · Cited by 13
Singh, A., Adam, A., Rodriguez, L., Peng, B., Wang, B., Xie, X., Shi, P., Homma, K., & Wang, T. (2023) · Pathogens · doi:10.3390/pathogens12040554 · Cited by 12
Augello, M., Bono, V., Rovito, R., Tincati, C., Monforte, A. D., & Marchetti, G. C. (2023) · AIDS · doi:10.1097/qad.0000000000003585 · Cited by 12
Montoya, B., Melo‐Silva, C. R., Tang, L., Kafle, S., Lidskiy, P., Bajusz, C., Vadovics, M., Muramatsu, H., Ábrahám, E., Lipinszki, Z., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.04.019 · Cited by 14
Metadata
- Authors
- Israelow, B., Mao, T., Klein, J., Song, E., Menasche, B., Omer, S. B., & Iwasaki, A.
- Affiliations
- Yale University (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Iwasaki, Akiko
- Venue
- Science Immunology
- Publisher
- openRxiv
- Published
- 2021-05-19
- Volume
- 6
- Issue
- 64
- Pages
- eabl4509-eabl4509
- ISSN
- 2470-9468 (ISSN-L)
- PMC
- PMC9047536
- OpenAlex
- W3197127917
- Cited by
- 189
- References
- 52
- Citations by year
- 2026: 9 · 2025: 23 · 2024: 26 · 2023: 43 · 2022: 67 · 2021: 21
- FWCI
- 13.06
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Science Immunology (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- Yale University
- National Institutes of Health (UL1TR001863)
- National Cancer Institute (F30CA239444)
- National Institute of General Medical Sciences (T32GM007205)
- National Institute of Allergy and Infectious Diseases (R01AI157488, K08AI163493, T32AI007019, T32AI007517)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Keywords
- SARS-CoV-2, adaptive immunity, viral clearance, humoral immunity, cell-mediated immunity, antibody response, mRNA vaccination, B.1.351 variant, Omicron variant, COVID-19 protection, mouse model
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
